Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Strategic Business Report 2017-2022 - Research and Markets

DUBLIN, Mar 01, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Global Strategic Business Report" report to their offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics in US$ Million.

The report profiles 27 companies including many key and niche players such as

• Alcobra Ltd. (Israel)
• Amarantus Bioscience Holdings, Inc. (US)
• Amedra Pharmaceuticals LLC (US)
• Curemark, LLC. (US)
• Eli Lilly and Company (US)
• Intellipharmaceutics International, Inc. (US)
• Janssen Global Services, LLC (US)
• Mallinckrodt PLC (Ireland)
• Mylan N.V. (The Netherlands)
• Neos Therapeutics, Inc. (US)
• Neurovance, Inc. (US)
• Noven Pharmaceuticals, Inc. (US)
• Pfizer Inc. (US)
• Shire plc (Ireland)
• Supernus Pharmaceuticals, Inc. (US)
• Tris Pharma, Inc. (US)

Key Topics Covered:

1. Market Overview

• ADHD Therapeutics: A Primer
• ADHD Therapeutics Market Outlook
• Factors Driving ADHD Therapeutics Market
• Changes in Insurance Coverage
• Addition of Formal Guidelines
• Low Diagnosis Threshold
• Advancements in Field of Medicine
• Unmet Needs
• Launch of Pipeline Drugs
• Factors Inhibiting ADHD Therapeutics Market
• Side Effects Related to Use of Stimulants to Treat ADHD
• Under-diagnosis of ADHD Condition
• Reduced Availability of Non-Stimulants in Certain Geographies
• Competitive Landscape
• Major ADHD Medications Available in the Market
• ADHD Medications Approved by FDA
• Patent Validity for Major ADHD Drugs

2. Noteworthy Trends In ADHD Therapeutics Market